E

Erika Hamilton

ORCID: 0000-0002-1911-0336

Publishes on Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology. 843 papers and 17.1k citations.

PubIndex Score99Top 1% · mid-careerHow it's scored

🌱#2 Emerging Leader in HER2/EGFR in Cancer Research 🌱#6 Emerging Leader in Cancer Treatment and Pharmacology 🌱#9 Emerging Leader in Advanced Breast Cancer Therapies

843Publications

17.1kTotal Citations

#2in HER2/EGFR in Cancer Research

First publication: 1982First senior author: 2016

Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology Estrogen and related hormone effects Monoclonal and Polyclonal Antibodies Research

Top publicationsby citations

Targeting HER2-positive breast cancer: advances and future directions

Sandra M. Swain, Erika Hamilton|Nature Reviews Drug Discovery|2022

Cited by 1k

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Paolo Tarantino, Giuseppe Curigliano, Erika Hamilton et al.|Journal of Clinical Oncology|2020

Cited by 801

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al.|Annals of Oncology|2021

Cited by 294

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Aditya Bardia, Funda Meric‐Bernstam, Rie Wong et al.|Journal of Clinical Oncology|2024

Cited by 158

Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study

Yoshiaki Nakamura, Tanios Bekaii‐Saab, Nobumasa Mizuno et al.|Journal of Clinical Oncology|2023

Cited by 100